Pfizer valmistaa Vivet Therapeuticsin geeniterapiaa Wilsonin tautiin
Pfizer Inc. ja Vivet Therapeutics ovat solmineet sopimuksen, jonka mukaan Pfizer valmistaa Vivetin tutkittavaa geeniterapiaa VTX-801, joka on tarkoitettu Wilsonin taudin hoitoon. Kliinisten kokeiden on määrä alkaa alkuvuodesta 2021.
U.S. Pharmaceutical giant Pfizer Inc. and France-based Vivet Therapeutics have signed a manufacturing agreement for Vivet's experimental gene therapy, VTX-801, which targets Wilson disease. Pfizer will produce the therapy for an upcoming Phase 1/2 clinical trial, scheduled to start in early 2021. Financial terms of the deal were not disclosed by either company.
VTX-801 is an investigational gene therapy aimed at treating Wilson disease, a rare and potentially fatal genetic disorder affecting the liver and other organs due to copper accumulation. The agreement builds upon an existing relationship established in March 2019, when Pfizer acquired a minority stake in Vivet and secured an option for a full acquisition, while also agreeing to collaborate on VTX-801's development.
Manufacturing of the gene therapy will take place at Pfizer's facility in Chapel Hill, North Carolina. The company has recently made substantial investments in its gene therapy manufacturing capabilities at this site, aiming to enhance its capacity for producing both clinical and commercial quantities. This expansion supports the goal of timely delivery for rare disease treatments.
Jean-Philippe Combal, CEO of Vivet Therapeutics, noted the complexity of gene therapy manufacturing and expressed hope that the agreement would strengthen the partnership with Pfizer and aid in VTX-801's long-term development. Seng Cheng, Chief Scientific Officer for Pfizer's Rare Disease Research Unit, highlighted the company's progress in gene therapy manufacturing and the strategic importance of supporting new therapies for patients.